Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Paclitaxel and Bevacizumab in Advanced Breast Cancer
NCT00368875Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2006
- Primary completion
- Dec 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 at 28 days and Objective Response Rate (CR + PR) up to 12 months. Started Jul 2006; status: completed.
02
Drugs
vorinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00368875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368875.